Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
Abatacept Combo May Reduce Immunotherapy-Related Myotoxicity in Cancer
March 8th 2023Abatacept plus ruxolitinib and screenings for concomitant respiratory muscle failure may be effective in reducing the rate of mortality related to immune checkpoint inhibitor–associated myocarditis among patients with cancer.
Camrelizumab Yields ‘Impressive’ Activity in Head & Neck Cancer Subtype
March 7th 2023Camrelizumab plus apatinib demonstrates impressive anti-tumor activity in a pretreated population with recurrent or metastatic nasopharyngeal carcinoma, although further research is needed, according to an expert from Memorial Sloan Kettering Cancer Center.
Mediterranean Diet Correlates With Responses to Melanoma Immunotherapy
February 28th 2023Previous research has identified a link between nutrients commonly found in a Mediterranean diet such as fiber, unsaturated fats, antioxidants, and polyphenols, and immunomodulatory/anti-tumor activities, according to a dietician from the University of Groningen.
Glasgow Prognostic Score May Predict Atezolizumab/Chemo Outcomes in SCLC
February 22nd 2023A favorable Glasgow prognostic score appears to correlate with improved overall survival and progression-free survival following treatment with atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Nivolumab Combo Yields PFS Benefit Regardless of PD-L1, c-MET status in RCC
February 21st 2023An ongoing exploratory biomarker analysis of the CheckMate 9ER trial set out to identify predictive biomarkers or a composite model of response of nivolumab/cabozantinib efficacy in advanced renal cell carcinoma.
Brexu-cel Yields Consistent Efficacy in R/R Mantle Cell Lymphoma in SOC Setting
February 20th 2023Prior exposure to recent bendamustine and having tumor-intrinsic features were associated with inferior efficacy outcomes following treatment with brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma.
Trilaciclib Reduces Neutropenia but Fails to Improve ORR in Metastatic CRC
February 13th 2023Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.